Florida
Shortage of Key Antibiotic Raises Concerns for Pensacola Mothers and Babies
The United States has a shortage of the only first-line medication recommended for pregnant women with syphilis to prevent passing it to their baby, even as congenital syphilis rates have been skyrocketing. Last July, drug manufacturer Pfizer issued a voluntary…
Last updated:
Key points
- Bicillin L-A, a critical antibiotic for treating syphilis in pregnant women, is in short supply.
- Local health departments are prioritizing access to this medication for expectant mothers and their infants.
- The shortage may worsen health disparities among vulnerable populations in Escambia County.
NewsWK — Pensacola and Escambia County residents may be alarmed to learn that the only U.S.-made antibiotic recommended for treating syphilis in pregnant women and newborns is currently in short supply. The injectable antibiotic, known as Bicillin L-A, is critical for preventing the transmission of syphilis from mothers to their babies, a condition that has been on the rise in recent years.
According to a report first published by Stateline, drug manufacturer Pfizer issued a voluntary recall of Bicillin L-A last July due to contamination issues. As a result, the U.S. Food and Drug Administration (FDA) projects that supplies will not stabilize until December 2027. This situation is particularly concerning given that there is only one manufacturing facility producing this essential medication, located in Michigan.
The effects of this antibiotic shortage could be felt locally, particularly among vulnerable populations. Local health departments and clinics in Pensacola are being urged to prioritize pregnant women and their infants for the available stock of Bicillin L-A, as congenital syphilis can lead to severe health complications, including stillbirth, blindness, and bone deformities. The rising rates of congenital syphilis have been reported as a significant public health issue, with experts warning that the current drug shortage may exacerbate these numbers.
Health officials in Florida are already facing challenges in ensuring that pregnant patients receive timely treatment. As noted by Elizabeth Finley from the National Coalition of STD Directors, the recall has led to a shortage that is unprecedented, jeopardizing the health of expectant mothers and their children. The report also highlights that disparities exist in healthcare access, with certain demographics, such as Indigenous and Black women, facing greater difficulties in obtaining prenatal care and necessary medications.
While some alternatives, like a medication imported from Portugal called Lentocilin, have been approved for temporary use, it is not a long-term solution. Local healthcare providers are advised to connect patients with available resources, but the lack of generics and the complexities of treatment regimens highlight a systemic issue that could worsen health outcomes in the community.
This article was produced with the assistance of AI and reviewed by our editorial team.
Based on reporting originally published by Stateline. Read the original story.
